Purity
> 95% as determined by HPLC
Buffer
Lyophilized from 0.22um filtered solution in PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization
Storage
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week
Reconstitution
Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
Introduction
Claudin-18.2 (CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies. Multiple clinical trials of CLDN18.2-targeted therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies, are ongoing, with some showing promising early results.
Keywords
Claudin-18.2; CLDN18.2
Citations
Publication ()
Have you cited DAG-WT1229 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
